The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune astrocytopathies characterized by predominant involvement of the optic nerves and spinal cord. In most patients, an IgG autoantibody binding to astrocytic aquaporin 4, the principal water channel of the central nervous system, is detected. Rituximab, a chimeric monoclonal antibody specific for the CD20 B-lymphocyte surface antigen, has been increasingly adopted as a first-line off-label treatment for patients with NMOSDs. OBJECTIVE: To perform a systematic review and a meta-analysis of the efficacy and safety of rituximab use in NMOSDs, considering the potential predictive factors related to patient response to rituximab in this disease. EVIDENCE REVIEW: English-language studies published between January 1, 2000, and July 31, 2015, were searched in the MEDLINE, Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov databases. Patient characteristics, outcome measures, treatment regimens, and recorded adverse effects were extracted. FINDINGS: Forty-six studies were included in the systematic review. Twenty-five studies that included 2 or more patients with NMOSDs treated with rituximab were included in the meta-analysis. Differences in the annualized relapse rate ratio and Expanded Disability Status Scale score before and after rituximab therapy were the main efficacy measures. Safety outcomes included the proportion of deaths, withdrawals because of toxic effects, and adverse effects. RESULTS: Among 46 studies involving 438 patients (381 female and 56 male [sex was not specified in 1 patient]; mean age at the outset of treatment, 32 years [age range, 2-77 years]), rituximab therapy resulted in a mean (SE) 0.79 (0.15) (95% CI, -1.08 to -0.49) reduction in the mean annualized relapse rate ratio and a mean (SE) 0.64 (0.27) (95% CI, -1.18 to -0.10) reduction in the mean Expanded Disability Status Scale score. A significant correlation was observed between disease duration and the Expanded Disability Status Scale score. Adverse effects were recorded in 114 of 438 (26%) patients treated with rituximab. Specifically, 45 patients (10.3%) experienced infusion-related adverse effects, 40 patients (9.1%) had an infection, 20 patients (4.6%) developed persistent leukopenia, 2 patients (0.5%) were diagnosed as having posterior reversible encephalopathy, and 7 patients (1.6%) died. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis provides evidence that rituximab therapy reduces the frequency of NMOSD relapses and neurological disability in patients with NMOSDs. However, the safety profile suggests caution in prescribing rituximab as a first-line therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In any case, the long-term persistence of (re-)activatable autoantigen-specific ThEx cells in patients in remission may well explain the less-than-perfect treatment efficacy of steroid-sparing agents, 64-67 depletion of CD19/CD20 memory B cells, 68,69 as well as exacerbation of disease by b -IFN. 27,70”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [69]
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. L., & Genain, C. P. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 585
Treatment of Neuromyelitis Optica With Rituximab
Jacob, A., Weinshenker, B. G., Violich, I., McLinskey, N., Krupp, L., Fox, R. J., Wingerchuk, D. M., Boggild, M., Constantinescu, C. S., Miller, A., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 460
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul‐Enein, F., Waters, P. J., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A. C., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 433
NMO-IgG predicts the outcome of recurrent optic neuritis
Matiello, M., Lennon, V. A., Jacob, A., Pittock, S. J., Lucchinetti, C. F., Wingerchuk, D. M., & Weinshenker, B. G. (2008) · Neurology · doi:10.1212/01.wnl.0000303817.82134.da · Cited by 364
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Dale, R. C., Brilot, F., Duffy, L. V., Twilt, M., Waldman, A. T., Narula, S., Muscal, E., Deiva, K., Andersen, E., Eyre, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000570 · Cited by 347
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes
Hinson, S. R., Romero, M. F., Popescu, B. F. G., Lucchinetti, C. F., Fryer, J. P., Wolburg, H., Fallier‐Becker, P., Noell, S., & Lennon, V. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109980108 · Cited by 335
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Kim, S., Huh, S., Lee, S. J., Joung, A., & Kim, H. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3071 · Cited by 323
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica
Mealy, M. A., Wingerchuk, D. M., Palace, J. A., Greenberg, B. M., & Levy, M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5699 · Cited by 303
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J. B., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
Kim, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica
Jiao, Y., Fryer, J. P., Lennon, V. A., Jenkins, S. M., Quek, A. M. L., Smith, C. Y., McKeon, A. B., Costanzi, C., Iorio, R., Weinshenker, B. G., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cb5c · Cited by 248
Self-citationRituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases
Rastetter, W. H., Molina, A., & White, C. A. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104249 · Cited by 213
Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica
Kim, S., Jeong, I. H., Hyun, J., Joung, A., Jo, H.-J., Hwang, S., Yun, S., Joo, J., & Kim, H. J. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1276 · Cited by 209
Ayzenberg, I., Kleiter, I., Schröder, A., Hellwig, K., Chan, A., Yamamura, T., & Gold, R. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1246 · Cited by 203
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
Iorio, R., Damato, V., Alboini, P. E., & Evoli, A. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7532-3 · Cited by 190
Self-citationImpact of rituximab on relapse rate and disability in neuromyelitis optica
Bedi, G. S., Brown, A. D., Delgado, S. R., Usmani, N., Lam, B. L., & Sheremata, W. A. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511404586 · Cited by 148
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica
Yang, C., Yang, L., Li, T., Zhang, D., Jin, W., Li, M., Su, N., Zhangning, N., Liu, Q., Shao, Z., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a1aac7 · Cited by 135
Greenberg, B. M., Graves, D. F., Remington, G. M., Hardeman, P., Mann, M., Karandikar, N. J., Stüve, O., Monson, N. L., & Frohman, E. M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511432896 · Cited by 114
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
Zéphir, H., Bernard‐Valnet, R., Lebrun‐Frénay, C., Outteryck, O., Audoin, B., Bourre, B., Pittion, S., Wiertlewski, S., Ouallet, J., Neau, J., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7852-y · Cited by 97
Rituximab does not reset defective early B cell tolerance checkpoints
Chamberlain, N., Massad, C., Oe, T., Cantaert, T., Herold, K. C., Meffre, E., & the Type 1 Diabetes TrialNet Pathway to Prevention Study Group (2015) · Journal of Clinical Investigation · doi:10.1172/jci83840 · Cited by 92
Nakashima, I., Takahashi, T., Cree, B., Kim, H. J., Suzuki, C., Genain, C. P., Vincent, T., Fujihara, K., Itoyama, Y., & Bar‐Or, A. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.12.011 · Cited by 87
Analysis of the treatment of neuromyelitis optica
Torres, J., Pruitt, A. A., Balcer, L. J., Galetta, S. L., Markowitz, C., & Dahodwala, N. A. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.02.012 · Cited by 85
Radaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V., Ferrè, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515594042 · Cited by 85
Iorio, R., Fryer, J. P., Hinson, S. R., Fallier‐Becker, P., Wolburg, H., Pittock, S. J., & Lennon, V. A. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.07.008 · Cited by 84
Self-citationRituximab Use in Pediatric Central Demyelinating Disease
Beres, S., Graves, J., & Waubant, E. L. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.02.007 · Cited by 69
Disease exacerbation after rituximab induction in neuromyelitis optica
Perumal, J. S., Kister, I., Howard, J., & Herbert, J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000061 · Cited by 69
Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus
Birnbaum, J., & Kerr, D. A. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0818 · Cited by 65
Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.
Mok, C. C., To, C. H., Mak, A., & Poon, W. L. (2008) · PubMed · Cited by 64
Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)
Capobianco, M. A. N., Malucchi, S., Sapio, A. D., Gilli, F., Sala, A., Bottero, R., Marnetto, F., Bozzo, C. D., & Bertolotto, A. (2007) · Neurological Sciences · doi:10.1007/s10072-007-0823-z · Cited by 63
Variable results after rituximab in neuromyelitis optica
Lindsey, J. W., Meulmester, K. M., Brod, S. A., Nelson, F. M., & Wolinsky, J. S. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.02.017 · Cited by 62
Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab
Pellkofer, H., Süßmair, C., Schulze, A., Hohlfeld, R., & Kümpfel, T. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106512 · Cited by 58
Iorio, R., Damato, V., Massimiliano Mirabella, A., Evoli, A., Marti, A., Plantone, D., Frisullo, G., & Batocchi, A. P. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6997-9 · Cited by 50
Self-citationRingelstein, M., Harmel, J., Distelmaier, F., Ingwersen, J., Menge, T., Hellwig, K., Kieseier, B. C., Mayatepek, E., Hartung, H., Kümpfel, T., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513498125 · Cited by 50
Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders
Ip, V. H. L., Lau, A. Y. L., Au, L. W. C., Fan, F. S. Y., Chan, A. Y. Y., Mok, V., & Wong, K. S. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.09.024 · Cited by 48
Rituximab as a first-line preventive treatment in pediatric NMOSDs
Longoni, G., Banwell, B., Filippi, M., & Yeh, E. A. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000046 · Cited by 46
Nasir, S., Kerr, D. A., & Birnbaum, J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.194 · Cited by 40
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica
Graves, J., Vinayagasundaram, U., Mowry, E. M., Matthews, I. R., Marino, J. A., Cheng, J., & Waubant, E. L. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2013.10.003 · Cited by 40
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
Leavitt, J. A. (2009) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(09)79219-1 · Cited by 40
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER RITUXIMAB INFUSION IN NEUROMYELITIS OPTICA
Sánchez-Carteyron, A., Alarcia, R., Ara, J. R., & Martín, J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dc1af3 · Cited by 37
Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica
Mahmood, N. A., Silver, K. M., Onel, K. B., Ko, M., & Javed, A. (2010) · Journal of Child Neurology · doi:10.1177/0883073810381445 · Cited by 32
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases
Gredler, V., Mader, S., Schanda, K., Hegen, H., Pauli, F. D., Kuenz, B., Deisenhammer, F., Berger, T., Reindl, M., & Lutterotti, A. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.02.024 · Cited by 25
Available evidence and outcome of off-label use of rituximab in clinical practice
Danés, I., Agustí, A., Vallano, A., Martínez, J., Alerany, C., Ferrer, A., López, A., Cortés-Hernández, J., & Bosch, J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1518-4 · Cited by 24
Bichuetti, D. B., de Oliveira, E. M. L., de Souza, N. A., Tintoré, M., & Gabbai, A. A. (2013) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130020 · Cited by 24
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin‐4 channelopathies
Iorio, R., & Pittock, S. J. (2014) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12103 · Cited by 20
Self-citationLate-onset neutropenia during long-term rituximab therapy in neuromyelitis optica
Plate, A., Havla, J. B., & Kümpfel, T. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2013.08.001 · Cited by 20
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment
Weinfurtner, K. M., Graves, J. S., Ness, J., Krupp, L., Milazzo, M. C., & Waubant, E. L. (2014) · Journal of Child Neurology · doi:10.1177/0883073814553974 · Cited by 20
Berger, J. R., Neltner, J. H., Smith, C. D., & Cambi, F. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.08.004 · Cited by 18
Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections
Feyissa, A. M., Singh, P., & Smith, R. G. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513483891 · Cited by 18
Rapid exacerbation of neuromyelitis optica after rituximab treatment
Dai, Y., Lü, T., Wang, Y., Fang, L., Li, R., Kermode, A. G., & Qiu, W. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.08.033 · Cited by 14
Patel, V. N., Griffith, N. C., Blackwood, E., Dias, M., & Cordato, D. J. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.03.007 · Cited by 12
Beyer, A.-M., Wandinger, K., Siebert, E., Zschenderlein, R., & Klehmet, J. (2007) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2007.08.018 · Cited by 12
Treatment-Resistant Depression and Aquaporin-4 Autoantibodies: Is There a Link?
Iorio, R. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.011 · Cited by 10
Self-citationBilateral Internuclear Ophthalmoplegia in a Patient with Devic’s Neuromyelitis Optica
García‐Martín, E., Pinilla, I., Pueyo, V., Gil, L., Martínez-Morales, J. A., & Fernandez, J. (2010) · Case Reports in Neurology · doi:10.1159/000322428 · Cited by 10
Neuromyelitis Optica in Child: Diagnostic and Therapeutic Challenges
Dembinski, K., Gieron-Korthals, M. A., Martinez, C. R., & Rodriguez, L. (2013) · Case Reports in Pediatrics · doi:10.1155/2013/124929 · Cited by 9
Cassinotto, C., Joux, J., Chausson, N., Smadja, D., & Cabre, P. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2007.10.009 · Cited by 9
Treatment of NMO relapse in the elderly: rituximab when plasma exchange fails?
Bourre, B., Lefaucheur, R., & Girault, C. (2013) · Acta Neurologica Belgica · doi:10.1007/s13760-013-0178-6 · Cited by 7
A case of longitudinally extensive transverse myelitis (LETM): neuromyelitis optica
Mangat, P., Ravindran, J., Cleland, L., & Limaye, V. S. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0936-7 · Cited by 7
Individualized Rituximab Treatment for Relapsing Neuromyelitis Optica: A Pediatric Case Report
He, D., Yu, Y., Yan, W., Dai, Q., Xu, Z., & Chu, L. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.01.039 · Cited by 6
Neuromyélite optique chez l’enfant. À propos de deux cas
Tosello, B., Halbert, C., Mancini, J., Chabrol, B., Boucraut, J., & Milh, M. (2012) · Archives de Pédiatrie · doi:10.1016/j.arcped.2012.05.019 · Cited by 5
Alsharoqi, I. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.09.206 · Cited by 5
Neuromyelitis optica: Case reports from Oman
Musafir, M. A., Kumar, S., Shaikhly, K., Zayed, A., & Walli, F. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.09.159 · Cited by 1
Flagged first, then by citations
Cited by
Sorted by citations
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 503
Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 376
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Contentti, E. C., & Correale, J. D. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 363
Sechi, E., Cacciaguerra, L., Chen, J. J.-W., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.885218 · Cited by 352
Metadata
- Authors
- Damato, V., Evoli, A., & Iorio, R.
- Affiliations
- Agostino Gemelli University Polyclinic (IT)
- Don Carlo Gnocchi Foundation (IT)
- Corresponding author
- Iorio, Raffaele
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 73
- Issue
- 11
- Pages
- 1342
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2524675862
- Cited by
- 290
- References
- 66
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 25 · 2023: 29 · 2022: 34 · 2021: 50 · 2020: 49 · 2019: 24 · 2018: 20 · 2017: 11 · 2016: 1
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- neuromyelitis optica spectrum disorder, rituximab, CD20, off-label drug use, aquaporin-4 antibodies, annualized relapse rate, Expanded Disability Status Scale, disability progression, treatment safety, disease duration, predictors of treatment response, autoimmune demyelinating disease, B-cell depletion therapy, relapse prevention
- MeSH terms
- Rituximab, Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunologic Factors, Male, Middle Aged, Neuromyelitis Optica, Outcome Assessment, Health Care, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
